Today enGene Holdings said it completed its business combination with Forbion European Acquisition. The company also announced a concurrent transaction financing.
Stock in enGene began trading today on the Nasdaq under the symbol ENGN.
Gross proceeds from the merger totaled approximately $138 million, which included funds held in the SPAC’s trust net of redemptions, and a concurrent, oversubscribed PIPE.
Forbion European earlier this year lost most of its trust value — 10,379,144 shares — to redemptions ahead of the merger vote.
As announced in May, the deal was to include $135 million in financing plus the SPAC’s $111 million in trust at that time. Read more.
